Yan Wang

Yan Wang

Auto-generated profile, based on publicly available information

Yan Wang

Shanxi Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2017 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
YWYan Wang
Yan Wang
FZFei Zhang
Fei Zhang
YLYu Liu
Yu Liu
SYSha Yin
Sha Yin
XPXuefen Pang
Xuefen Pang
ZWZehui Wei
Zehui Wei
Purpose: To investigate the effect and mechanism of nebivolol on aortic remodeling in N-nitro-l-arginine methyl ester (l-NAME)-induced hypertension. Methods: Male Sprague–Dawley rats were treated with equal volumes of drinking water or l-NAME (60 mg/kg/day), alone or in combination with nebivolol (8 mg/kg/day) or atenolol (80 mg/kg/day) by gavage for 8 weeks. Systolic blood pressure (SBP), aortic morphometry, plasma nitric oxide (NO) levels, nitric oxide synthase (NOS) activity, and relaxation of aorta to acetylcholine were determined. Protein expression of endothelial NOS (eNOS), Akt, and NADPH oxidase (Nox) was evaluated. Results: l-NAME-treated rats showed an elevated SBP associated with aortic remodeling. l-NAME-treated rats showed reduced plasma NO levels and NOS activity and increased reactive oxygen species (ROS). Protein expression of eNOS, eNOS phosphorylated at Ser1177 (p-eNOS), Akt, and Akt phosphorylated at Ser473 (p-Akt) decreased, whereas that of Nox2, Nox4, and p22phox increased in the aortas from l-NAME-treated rats. Nebivolol treatment reduced SBP and ameliorated aortic remodeling. The effects of nebivolol were accompanied by increasing NO levels, NOS activity, and expression of eNOS, p-eNOS, Akt, and p-Akt, as well as reduction of ROS generation and Nox2, Nox4, and p22phox expression. These effects of nebivolol were not reproduced by atenolol. Conclusion: Our data indicate a protective role of nebivolol on the high blood pressure and vascular remodeling induced by l-NAME. The beneficial vascular effect of nebivolol is mediated by the upregulation of eNOS and inhibition of oxidative stress.

18 April 2023 in Renal Failure
Verified
Journal Article
Open access
JBJiang Bai
Jiang Bai
TZTianxiang Zhang
Tianxiang Zhang
YWYan Wang
Yan Wang
JCJiajing Cao
Jiajing Cao
ZDZihui Duan
Zihui Duan
QGQiang Guo
Qiang Guo
To systematically review the incidence and risk factors for recurrent FSGS after kidney transplantation.We searched PubMed, Embase, Medline, Web of Science, the Cochrane Library, CNKI, CBMdisc, Wan...

23 June 2018 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
YWYan Wang
Yan Wang
WAWenjing An
Wenjing An
FZFei Zhang
Fei Zhang
MNMengzhen Niu
Mengzhen Niu
YLYu Liu
Yu Liu
RSRuizan Shi
Ruizan Shi

1 October 2018 in Pharmacological Reports
Verified
Journal Article
Closed access
YWYan Wang
Yan Wang
MNMengzhen Niu
Mengzhen Niu
SYSha Yin
Sha Yin
FZFei Zhang
Fei Zhang
RSRuizan Shi
Ruizan Shi

31 March 2023 in International Heart Journal
Verified
Journal Article
Open access
PDF file
XLXinxin Li
Xinxin Li
QLQiuping Li
Qiuping Li
LWLijun Wu
Lijun Wu
YWYan Wang
Yan Wang
Vascular endothelial insulin resistance (IR) is an important risk factor in the development of vascular complications in diabetes. Prolonged endoplasmic reticulum stress (ERS) contributes to the development and progression of endothelial IR. The current study assessed the effects and mechanism of nebivolol on vascular IR in Goto-Kakizaki (GK) rats and endothelial IR induced by high glucose (33.3 mmol/L) associated with high insulin (10−7 mol/L) in human aortic endothelial cells (HAECs). Rats were divided into Wistar, Wistar + Neb (Wistar rats treated with nebivolol, 10 mg/kg, ig), GK, and GK + Neb (GK rats treated with nebivolol, 10 mg/kg, ig). GK rats showed hyperglycemia, dyslipidemia, impaired glucose homeostasis, metabolic IR, reduced relaxation to insulin, and lower serum nitric oxide (NO) level. Treatment with nebivolol for 4 months ameliorated insulin's vasorelaxation and NO production, and relieved dyslipidemia in GK rats. Additionally, nebivolol increased glucose uptake and NO level in the endothelial IR group in vitro. Nebivolol increased aortic expressions of IRS-1/PI3K/Akt/eNOS relative proteins and GLUT4 and reduced expressions of ERS markers (ATF6, GRP78, and CHOP, p-JNK/JNK). Furthermore, both nebivolol and TUDCA (ERS inhibitor) alleviated the attenuated IRS-1PI3K/Akt/eNOS pathway and enhanced ERS in HAECs IR. Tunicamycin (ERS inducer) not only induced endothelial IR but also blocked nebivolol's alleviation on the IRS-1PI3K/Akt/eNOS pathway and ERS. Nebivolol ameliorated endothelial IR partially by inhibiting ERS and then regulating the IRS-1/PI3K/Akt/eNOS signal.

28 January 2016 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
PDF file
YWYan Wang
Yan Wang
XDXiushan Dong
Xiushan Dong
Background: Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, induces endothelial dysfunction. Nebivolol, a highly selective β1-adrenergic receptor (AR) blocker, is the only beta-blocker known to induce vascular production of nitric oxide. Objective: The present study was designed to evaluate the effect and mechanism of nebivolol on ADMA-induced vascular response in rat aorta in vitro. Methods: In vitro, the effects of nebivolol and ADMA on resting tone or contraction induced by phenylephrine (PE, 10−6 mol/L) and relaxation induced by acetylcholine (Ach, 10−10–10−5 mol/L) were evaluated. Results: ADMA in a concentration-dependent manner increased the resting and PE-induced tone and reduced Ach-induced relaxation. Nebivolol inhibited the ADMA-induced enhancements in tone and reversed the effects of ADMA on Ach-induced relaxation. These effects of nebivolol were blocked by selective β3 receptor blocker cyanopindolol (1 μM), but not by selective β2 receptor blocker butoxamine (50 μM). Conclusions: Nebivolol ameliorates the ADMA-induced vascular responses in rat aorta, at least in part, by mechanisms involving β3 adrenoceptor.